{"disease":{"id":"scchn","name":"scchn"},"drugs":{"marketed":[{"drug_id":"chembl-chembl1201577","indication_name":"Locally or regionally advanced SCCHN","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CETUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201577","indication_name":"Recurrent locoregional or metastatic SCCHN","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CETUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201577","indication_name":"Recurrent or metastatic SCCHN after platinum-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CETUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"pf-06823859","indication_name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02369874","title":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03452137","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":406,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07125755","title":"Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":386,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03226756","title":"Nivolumab in Recurrent and/or Metastatic SCCHN","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04925284","title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT02001623","title":"Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT07259915","title":"Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Centre Henri Becquerel","has_results":false},{"nct_id":"NCT02573259","title":"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03771820","title":"Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":136,"lead_sponsor_name":"NanoCarrier Co., Ltd.","has_results":false},{"nct_id":"NCT02499120","title":"Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04844073","title":"A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01303237","title":"A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","phase":"","overall_status":"TERMINATED","enrollment_count":88,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT05070247","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":61,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04989387","title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07348887","title":"Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04424641","title":"A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"Genmab","has_results":true},{"nct_id":"NCT06736379","title":"Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"VLP Therapeutics","has_results":false},{"nct_id":"NCT03357757","title":"Avelumab With Valproic Acid in Virus-associated Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"AHS Cancer Control Alberta","has_results":false},{"nct_id":"NCT05057247","title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Glenn J. Hanna","has_results":true},{"nct_id":"NCT07310771","title":"Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT03538028","title":"A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Incyte Biosciences International Sàrl","has_results":false},{"nct_id":"NCT07405645","title":"Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT02205398","title":"Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06974734","title":"A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04107103","title":"Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"AHS Cancer Control Alberta","has_results":false},{"nct_id":"NCT04052204","title":"Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03405142","title":"Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Eben Rosenthal","has_results":true},{"nct_id":"NCT00627835","title":"Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}